Research programme: diabetes therapeutics - Hyundai Pharmaceuticals

Drug Profile

Research programme: diabetes therapeutics - Hyundai Pharmaceuticals

Alternative Names: GPR-6277; HD-0472936; HD-2355; HD-2356; HD-2936; HD-6277; HOB-046; HOB-047

Latest Information Update: 12 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hyundai Pharmaceutical
  • Class Antihypoglycaemics
  • Mechanism of Action 11-beta hydroxysteroid dehydrogenase inhibitors; FFAR1 protein stimulants; GPR119 protein agonists; Peroxisome proliferator-activated receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Type 2 diabetes mellitus

Most Recent Events

  • 22 Jun 2018 Pharmacodynamics data from preclinical studies in Type-2 diabetes mellitus presented at the 78th Annual Scientific Sessions of the American Diabetes Association (ADA-2018)
  • 09 Jun 2017 Pharmacodynamics data from a preclinical trial in Type-2 diabetes mellitus presented at the 77th Annual Scientific Sessions of the American Diabetes Association (ADA-2017)
  • 09 Jun 2017 Pharmacokinetics data from a preclinical trial in Type-2 diabetes mellitus presented at the 77th Annual Scientific Sessions of the American Diabetes Association (ADA-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top